/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ABSCI CORPORATION

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.28 0.0858(8.58%) ABSI at 04 Dec 2025 04:24 PM Biotechnology
Lowest Today 3.05
Highest Today 3.3
Today’s Open 3.05
Prev. Close 3.03
52 Week High 6.33
52 Week Low 2.01
Day’s Range: Low 3.05 High 3.3
52-Week Range: Low 2.01 High 6.33
1 day return -
1 Week return +4.1
1 month return -16.45
3 month return +38.07
6 month return +15.58
1 year return +6.79
3 year return +38.07
5 year return -
10 year return -

Institutional Holdings

FMR Inc 12.80

ARK Genomic Revolution ETF 7.78

ARK Investment Management LLC 6.72

ARK Genomic Revolution 6.34

Fidelity Growth Compy Commingled Pl S 6.19

BlackRock Inc 5.59

Redmile Group, LLC 5.52

Fidelity Growth Company Fund 4.34

Vanguard Group Inc 4.31

Vanguard Total Stock Mkt Idx Inv 2.73

Fred Alger Management, LLC 2.63

Woodline Partners LP 1.98

iShares Russell 2000 ETF 1.74

Columbia Acorn Inst 1.72

Ameriprise Financial Inc 1.72

Alger Small Cap Focus Composite 1.65

Alger Small Cap Focus I 1.65

Geode Capital Management, LLC 1.64

Fidelity Growth Company K6 1.49

Massachusetts Financial Services Company 1.49

UBS Group AG 1.28

Bank of America Corp 1.25

Fidelity Series Growth Company 1.23

State Street Corp 1.21

Fidelity Select Biotechnology 1.19

Royce & Associates, LP 1.02

MFS New Discovery I 1.00

Sumitomo Mitsui Trust Group Inc 0.98

Amova Asset Management Americas, Inc 0.97

Morgan Stanley - Brokerage Accounts 0.84

Fidelity Small Cap Index 0.73

Vanguard Institutional Extnd Mkt Idx Tr 0.69

Casdin Capital, LLC 0.65

Royce Micro Cap Trust 0.61

Dimensional Fund Advisors, Inc. 0.56

Charles Schwab Investment Management Inc 0.55

iShares Russell 2000 Growth ETF 0.53

Alger Small Cap Growth B 0.44

iShares Biotechnology ETF 0.44

Vanguard Russell 2000 ETF 0.35

Market Status

Strong Buy: 5

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 455.63 M

PB Ratio 2.2662

PE Ratio 0.0

Enterprise Value 330.42 M

Total Assets 213.61 M

Volume 3099880

Company Financials

Annual Revenue FY23:6937000 6.9M, FY22:5747000 5.7M, FY21:4782000 4.8M, FY20:4780000 4.8M, FY19:2060000 2.1M

Annual Profit FY23:null 0.0M, FY22:5747000 5.7M, FY21:4782000 4.8M, FY20:4780000 4.8M, FY19:2060000 2.1M

Annual Net worth FY23:-106492000 -106.5M, FY22:-104904000 -104.9M, FY21:-100960000 -101.0M, FY20:-14569000 -14.6M, FY19:-6801000 -6.8M

Quarterly Revenue Q3/2025:378000 0.4M, Q2/2025:593000 0.6M, Q1/2025:1179000 1.2M, Q3/2024:1701000 1.7M, Q2/2024:1270000 1.3M

Quarterly Profit Q3/2025:378000 0.4M, Q2/2025:-19865000 -19.9M, Q1/2025:-15185000 -15.2M, Q3/2024:1701000 1.7M, Q2/2024:-2114000 -2.1M

Quarterly Net worth Q3/2025:-28706000 -28.7M, Q2/2025:-30569000 -30.6M, Q1/2025:-26346000 -26.3M, Q3/2024:-27398000 -27.4M, Q2/2024:-24750000 -24.8M

Fund house & investment objective

Company Information Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Organisation Biotechnology

Employees 156

Industry Biotechnology

CEO Mr. Sean McClain

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow